Author:
Minami Hironobu,Sai Kimie,Saeki Mayumi,Saito Yoshiro,Ozawa Shogo,Suzuki Kazuhiro,Kaniwa Nahoko,Sawada Jun-ichi,Hamaguchi Tetsuya,Yamamoto Noboru,Shirao Kuniaki,Yamada Yasuhide,Ohmatsu Hironobu,Kubota Kaoru,Yoshida Teruhiko,Ohtsu Atsushi,Saijo Nagahiro
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics
Reference32 articles.
1. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins;Garcia-Carbonero;Clin Cancer Res,2002
2. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions;Slatter;Drug Metab Dispos,1997
3. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes;Iyer;J Clin Invest,1998
4. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients;De Forni;Cancer Res,1994
5. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea;Gupta;Cancer Res,1994
Cited by
254 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献